Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

INVA - Innoviva, Inc.


IEX Last Trade
17.515
-0.020   -0.114%

Share volume: 12,322
Last Updated: Fri 27 Dec 2024 08:30:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.90%

PREVIOUS CLOSE
CHG
CHG%

$17.54
-0.02
-0.11%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
48%
Profitability 70%
Dept financing 27%
Liquidity 75%
Performance 25%
Company vs Stock growth
vs
Performance
5 Days
-0.79%
1 Month
-7.35%
3 Months
-8.64%
6 Months
8.95%
1 Year
8.48%
2 Year
34.02%
Key data
Stock price
$17.52
P/E Ratio 
8.34
DAY RANGE
$17.42 - $17.70
EPS 
$1.71
52 WEEK RANGE
$14.55 - $21.28
52 WEEK CHANGE
$10.04
MARKET CAP 
1.212 B
YIELD 
N/A
SHARES OUTSTANDING 
62.562 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/30/2024
BETA 
0.61
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$848,405
AVERAGE 30 VOLUME 
$640,797
Company detail
CEO: Pavel Raifeld
Region: US
Website: inva.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.

Recent news